
    
      Pregnant women 18 years or older with a history of chronic opioid use, opioid use disorder or
      women on medication assisted treatment (MAT), will be enrolled in the study and randomly
      assigned to one of two study groups. The first group will receive a Lidocaine/Menthol patch
      at the time of her Cesarean delivery, the second will receive placement of the Ambu ACTion
      infusion pain system at the time of the C-section. This device will be set up to infuse
      0.125% of bupivacaine for 48-60hrs postoperatively at a rate of 8cc/hr.
    
  